Real-World Data Affirms Next-Gen TAVR Device Advantage
TVT registry compares outcomes with Evolut FX and Pro+
Stay updated with breaking news from Johnk Forrest. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TVT registry compares outcomes with Evolut FX and Pro+
Student research – especially the thesis – and faculty mentors were celebrated at Student Research Day on May 9, 2023.
The number of deaths and disabling strokes among patients at low surgical risk who were treated with transcatheter aortic valve replacement (TAVR) remained lower at three years, but not significantly lower, following the TAVR procedure compared with patients who received conventional surgical aortic valve replacement (SAVR), according to new data being presented at the American College of Cardiology's Annual Scientific Session Together With the World Congress of Cardiology.
NEW ORLEANS — At 3 years, patients with severe aortic stenosis at low surgical risk who had transcatheter aortic valve replacement with a self-expanding valve continued to have lower risk for death or stroke than those who had surgical AVR. In the main results of the Evolut Low Risk Trial, risk for all-cause mortality or disabling stroke at 2 years was numerically lower and noninferior in
Rate of deaths, disabling strokes not significantly different compared to conventional surgery